A Phase I Trial of Recombinant Human Thrombopoietin in Patients With Delayed Platelet Recovery After Hematopoietic Stem Cell Transplantation

Richard A. Nash, Razelle Kurzrock, John DiPersio, Julie Vose, Charles Linker, Dipnarine Maharaj, Auayporn P. Nademanee, Robert Negrin, Stephen Nimer, Howard Shulman, Mark Ashby, Dennie Jones, Frederick R. Appelbaum, Richard Champlin

Research output: Contribution to journalArticle

63 Scopus citations

Abstract

Delayed platelet recovery is a significant complication after both autologous and allogeneic hematopoietic stem cell transplantation (HSCT). A multicenter, phase I dose-escalation study of recombinant human thrombopoietin (rhTPO) was conducted to assess its safety and to obtain preliminary data on its efficacy in patients with persistent severe thrombocytopenia (<20,000/μL) >35 days after HSCT. Thirty-eight patients, 37 of whom were evaluable, were enrolled in the study from April 1996 through January 1997. rhTPO was administered at doses of 0.6, 1.2, and 2.4 μg/kg as a single dose (group A) or in multiple doses every 3 days for a total of 5 doses (group B). No significant adverse effects were observed. Ten patients had recovery of platelet counts during the 28-day study period; 3 of these 10 had an increase in marrow megakaryocyte content 7 days after completing treatment with rhTPO. When all baseline marrows were compared with samples after rhTPO treatment, there was no difference in marrow megakaryocyte content (P = 0.49). This study design could not answer the question of whether the recoveries of platelet counts observed in some patients were spontaneous or influenced by rhTPO treatment; nonetheless, the authors found no correlation between the dose of rhTPO and the recovery of platelet counts. Increases in serum TPO levels were dose-dependent and remained significantly elevated for up to 72 hours after treatment. To evaluate response, further studies of treatment strategies with rhTPO in patients with delayed platelet recovery are required.

Original languageEnglish (US)
Pages (from-to)25-34
Number of pages10
JournalBiology of Blood and Marrow Transplantation
Volume6
Issue number1
DOIs
StatePublished - 2000

Keywords

  • Marrow transplantation
  • Megakaryocytes
  • Thrombocytopenia

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'A Phase I Trial of Recombinant Human Thrombopoietin in Patients With Delayed Platelet Recovery After Hematopoietic Stem Cell Transplantation'. Together they form a unique fingerprint.

  • Cite this

    Nash, R. A., Kurzrock, R., DiPersio, J., Vose, J., Linker, C., Maharaj, D., Nademanee, A. P., Negrin, R., Nimer, S., Shulman, H., Ashby, M., Jones, D., Appelbaum, F. R., & Champlin, R. (2000). A Phase I Trial of Recombinant Human Thrombopoietin in Patients With Delayed Platelet Recovery After Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 6(1), 25-34. https://doi.org/10.1016/S1083-8791(00)70049-8